Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Curcuminoids, the active polyphenolic compounds found in turmeric (Curcuma longa), have been investigated for their potential benefits in treating colitis, particularly inflammatory bowel diseases (IBD) such as ulcerative colitis. There is a moderate level of scientific evidence supporting their use in this context. Multiple preclinical studies have demonstrated that curcuminoids possess potent anti-inflammatory properties, inhibiting pathways such as NF-κB and reducing the production of pro-inflammatory cytokines. These mechanisms are relevant to the pathophysiology of colitis, which is characterized by chronic intestinal inflammation.

A number of small to moderate-sized randomized controlled trials (RCTs) in humans suggest curcuminoids may help maintain remission in ulcerative colitis. For example, a 2006 double-blind, placebo-controlled trial (Hanai et al., Clinical Gastroenterology and Hepatology) found that patients receiving curcumin in addition to standard therapy had significantly lower relapse rates compared to placebo. Meta-analyses and systematic reviews (e.g., Ng et al., Journal of Crohn's and Colitis, 2013) generally conclude that curcumin is a promising adjunctive therapy for ulcerative colitis but call for larger and longer-duration studies to confirm efficacy and safety.

Overall, while the evidence base is not as robust as for some conventional therapies, curcuminoids are supported by a combination of mechanistic rationale, preclinical data, and emerging clinical trial evidence. However, their use should be considered as adjunctive rather than primary therapy, and patients should consult healthcare providers before using them for colitis.

More about Curcuminoid
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Curcuminoid

Products containing Curcuminoid